ReviewFrontiers in immunology2026
Aminoacyl-tRNA synthetases in tumor immunity: canonical translation, source-resolved immune circuits and therapeutic opportunities.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aminoacyl-tRNA synthetases (aaRSs) generate the aminoacyl-tRNA pool required for protein synthesis, yet selected family members also participate in nutrient sensing, stress adaptation, metabolite-dependent protein modification and extracellular immune communication. This dual biology creates a recurrent interpretive problem in cancer: an aaRS signal can reflect canonical translational demand in tumor cells, a mitochondrial program specific to immune cells, protein modification driven by lactate or amino acids, an interferon-responsive state, a secreted ligand or extracellular vesicle cargo. This review provides a mechanistic, critically appraised synthesis rather than a catalog of the aaRS family. We reconnect aminoacylation, codon-dependent translation and aaRS-specific translational stress with tumor biology and then apply a source-resolved framework based on cellular source, molecular form, localization, receiving pathway and immune output. Mechanistic strength and clinical maturity are graded independently, with direct evidence of immune function recorded separately. Representative mechanisms include substrate-specific AARS1/AARS2 lactylation, context-dependent LARS1 programs driven by codon demand, LARS2-dependent mitochondrial translation in tumor-infiltrating regulatory T cells (TI-Tregs) and regulatory B cells (Bregs), activation of Toll-like receptor 2/6 (TLR2/6) by the unique domain embedded in CARS1 (UNE-C1), WARS1 tryptophanylation intrinsic to CD8+ T cells, KARS1 and GARS1 circuits that depend on molecular form, and additional QARS1, MARS1, RARS1 and VARS1 mechanisms. Several modules show strong preclinical immune causality and human association, but none has prospective clinical validation in treated patients. aaRS-informed biomarkers and therapeutic targeting should therefore be developed as complementary, context-dependent strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.